IPP Bureau

Gland Pharma receives USFDA approval for Eribulin Mesylate Injection
Gland Pharma receives USFDA approval for Eribulin Mesylate Injection

By IPP Bureau - April 07, 2024

The Product is expected to be the first generic approval on the market

Pluss unveils Celsure XL VIP pallets
Pluss unveils Celsure XL VIP pallets

By IPP Bureau - April 07, 2024

A game changing solution for the pharmaceutical industry

Wacker and Pantherna intensify collaboration in the development and production of mRNA biopharmaceuticals
Wacker and Pantherna intensify collaboration in the development and production of mRNA biopharmaceuticals

By IPP Bureau - April 07, 2024

Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry

LANXESS showcases extensive portfolio for the cosmetics industry at in-cosmetics Global
LANXESS showcases extensive portfolio for the cosmetics industry at in-cosmetics Global

By IPP Bureau - April 07, 2024

Highly effective preservation solutions ensuring the safety and protection of personal care products

Cipla Patalganga facility gets 6 USFDA observations
Cipla Patalganga facility gets 6 USFDA observations

By IPP Bureau - April 07, 2024

The regulator carried out a routine current Good Manufacturing Practices (cGMP) inspection from March 28 to April 4.

USFDA approves Bristol Myers and 2seventy bio’s Abecma for triple-class exposed multiple myeloma
USFDA approves Bristol Myers and 2seventy bio’s Abecma for triple-class exposed multiple myeloma

By IPP Bureau - April 06, 2024

Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial

Enhertu approved in the US as first tumour-agnostic HER2-directed therapy
Enhertu approved in the US as first tumour-agnostic HER2-directed therapy

By IPP Bureau - April 06, 2024

Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers

Imfinzi significantly improved overall survival and progression-free survival in ADRIATIC Phase III trial
Imfinzi significantly improved overall survival and progression-free survival in ADRIATIC Phase III trial

By IPP Bureau - April 06, 2024

First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial

Pfizer’s Velsipity UK approval will raise competition in ulcerative colitis market, says GlobalData
Pfizer’s Velsipity UK approval will raise competition in ulcerative colitis market, says GlobalData

By IPP Bureau - April 06, 2024

The approval marks a significant milestone for the American pharmaceutical company in the field of UC

Healthcare Triangle partners with Cynomi to enhance cybersecurity in healthcare
Healthcare Triangle partners with Cynomi to enhance cybersecurity in healthcare

By IPP Bureau - April 05, 2024

Aster DM Healthcare concludes separation of India and GCC businesses
Aster DM Healthcare concludes separation of India and GCC businesses

By IPP Bureau - April 05, 2024

The company plans to add 1700 beds by FY27 through the organic route

Lupin appoints Dr. Ranjana Pathak as Chief Quality Officer
Lupin appoints Dr. Ranjana Pathak as Chief Quality Officer

By IPP Bureau - April 05, 2024

Dabur India expects mid-single digit revenue growth in Q4
Dabur India expects mid-single digit revenue growth in Q4

By IPP Bureau - April 05, 2024

International Business is expected to register double-digit growth in constant currency terms

Merck initiates Phase 3 clinical trial of investigational oral KRAS G12C inhibitor MK-1084
Merck initiates Phase 3 clinical trial of investigational oral KRAS G12C inhibitor MK-1084

By IPP Bureau - April 05, 2024

For the first-line treatment of certain patients with metastatic non-small cell lung cancer

Abbott receives FDA approval for TriClip
Abbott receives FDA approval for TriClip

By IPP Bureau - April 04, 2024

TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery

Latest Stories

Interviews

Packaging